Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

FDMT holding history

4D Molecular Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

FDMT overviewAll 13F holders of FDMTFull Q2 2026 holdings

Shares (Q2 2026)
256,673
Value
$3.41M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of FDMT by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026256,673$3.41M<0.1%+98,553+62.3%AddedHolders
Q1 2026158,120$1.47M<0.1%−73,172−31.6%ReducedHolders
Q4 2025231,292$1.73M<0.1%+136,392+143.7%AddedHolders
Q3 202594,900$824.7K<0.1%−1,619−1.7%ReducedHolders
Q2 202596,519$358.1K<0.1%−139,926−59.2%ReducedHolders
Q1 2025236,445$763.7K<0.1%+138,881+142.3%AddedHolders
Q4 202497,564$543.4K<0.1%+17,275+21.5%AddedHolders
Q3 202480,289$867.9K<0.1%+13,149+19.6%AddedHolders
Q2 202467,140$1.41M<0.1%−307,050−82.1%ReducedHolders
Q1 2024374,190$11.9M<0.1%+288,139+334.8%AddedHolders
Q4 202386,051$1.74M<0.1%+41,154+91.7%AddedHolders
Q3 202344,897$571.5K<0.1%−8,953−16.6%ReducedHolders
Q2 202353,850$973.1K<0.1%+1,451+2.8%AddedHolders
Q1 202352,399$900.7K<0.1%+11,671+28.7%AddedHolders
Q4 202240,728$904.6K<0.1%+40,728NewHolders
Q3 20220$00.0%−35−100.0%Sold outHolders
Q2 202235$00.0%−70,199−100.0%ReducedHolders
Q1 202270,234$1.06M<0.1%+884+1.3%AddedHolders
Q4 202169,350$1.52M<0.1%+68,094+5,421.5%AddedHolders
Q3 20211,256$34.0K<0.1%+1,256NewHolders
Q2 20210$00.0%−20,592−100.0%Sold outHolders
Q1 202120,592$893.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.